Zhu, Chenjing and Menyhart, Otilia and Győrffy, Balázs and He, Xia (2019) The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy. BMC CANCER, 19 (1). ISSN 1471-2407
|
Text
s12885-019-6260-6.pdf Download (2MB) | Preview |
Abstract
Background: Despite much effort on the treatment of breast cancer over the decades, a great uncertainty regarding the appropriate molecular biomarkers and optimal therapeutic strategy still exists. This research was performed to analyze the association of SPAG5 gene expression with clinicopathological factors and survival outcomes. Methods: We used a breast cancer database including 5667 patients with a mean follow-up of 69 months. Kaplan-Meier survival analyses for relapse free survival (RFS), overall survival (OS), and distant metastasis-free survival (DMFS) were performed. In addition, ROC analysis was performed to validate SPAG5 as a prognostic candidate gene. Results: Mean SPAG5 expression value was significantly higher with some clinicopathological factors that resulted in tumor promotion and progression, including poor differentiated type, HER2 positive or TP53 mutated breast cancer. Based on ROC-analysis SPAG 5 is a suitable prognostic marker of poor survival. In patients who received chemotherapy alone, SPAG5 had only a moderate and not significant predictive impact on survival outcomes. However, in hormonal therapy, high SPAG5 expression could strongly predict prognosis with detrimental RFS (HR = 1.57, 95% CI 1.2-2.06, p = 0.001), OS (HR = 2, 95% CI 1.05-3.8, p = 0.03) and DMFS (HR = 2.36, 95% CI 1.57-3.54, p < 0.001), respectively. In addition, SPAG5 could only serve as a survival predictor in ER+, but not ER- breast cancer patients. Patients might also be at an increased risk of relapse despite being diagnosed with a lower grade cancer (well differentiated type). Conclusions: SPAG5 could be used as an independent prognostic and predictive biomarker that might have clinical utility, especially in ER+ breast cancer patients who received hormonal therapy. © 2019 The Author(s).
| Item Type: | Article |
|---|---|
| Additional Information: | Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Affiliated Cancer Hospital of Nanjing Medical University, 42 Baiziting, Nanjing, Jiangsu, 210009, China TTK Cancer Biomarker Research Group, Institute of Enzymology, Budapest, Hungary Second Department of Pediatrics, Semmelweis University, Budapest, H-1094, Hungary Export Date: 19 November 2019 CODEN: BCMAC Correspondence Address: Zhu, C.; Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Affiliated Cancer Hospital of Nanjing Medical University, 42 Baiziting, China; email: drchenjingzhu@gmail.com |
| Uncontrolled Keywords: | CHEMOTHERAPY; Prognosis; breast cancer; ENDOCRINE THERAPY; SPAG5; |
| Subjects: | R Medicine / orvostudomány > RC Internal medicine / belgyógyászat > RC0254 Neoplasms. Tumors. Oncology (including Cancer) / daganatok, tumorok, onkológia |
| SWORD Depositor: | MTMT SWORD |
| Depositing User: | MTMT SWORD |
| Date Deposited: | 29 Nov 2019 15:53 |
| Last Modified: | 29 Nov 2019 15:53 |
| URI: | http://real.mtak.hu/id/eprint/104002 |
Actions (login required)
 |
Edit Item |
